Genetic variants of EBI3, tumor Epstein-Barr virus, and human cytomegalovirus status in HPV-negative oral cancer
DOI:
https://doi.org/10.1590/1678-7765-2025-0492Keywords:
Mouth Neoplasms, Oral Squamous Cell Carcinoma, Epstein-Barr virus, Human Cytomegalovirus, Epstein-Barr Virus induced gene 3, Single nucleotide polymorphismsAbstract
Oral squamous cell carcinoma (OSCC), a malignancy with high recurrence rate and poor survival, may be influenced by immune-related genetic variations and oncogenic viruses. Objective This study evaluated the clinical relevance of EBI3 polymorphisms, along with tumor Epstein–Barr virus (EBV) and Human Cytomegalovirus (HCMV) status, in prognostically adverse HPV-negative OSCCs. Methodology EBI3 (rs4740, rs4905, rs428253) genotyping was performed by qPCR in 95 HPV-negative OSCC patients and 108 age- and sex-matched controls. Tumor HPV, EBV, and HCMV status were assessed by qPCR. EBV viral load was calculated by exponential approach and a relative estimate of EBV copies per 105 cells. Associations with overall survival (OS) and recurrence-free survival (RFS) were evaluated by Kaplan-Meier and Cox regression analyses. Results EBV-positive tumors showed a significant association with increasing nodal stage (P=0.020). EBV viral load stratification (negative, low, high) presented a non-significant trend toward association with advanced tumor stage (P=0.060). Notably, EBI3 rs428253 predicted worse OS in EBV-positive patients, whereas rs4740 and rs4905 variants were associated with advanced tumor stage (P=0.024 and P=0.018). rs4740 and rs4905 variants were inversely associated with OSCC risk in dominant and overdominant models. Analysis detected HCMV in 7.4% of tumors but was not clinically relevant. Conclusions EBI3 genetic variants and EBV status may have prognostic relevance in HPV-negative OSCC. EBV may interact with the host genetics to influence nodal metastases and outcomes, suggesting a potential EBV-EBI3 axis, which warrants further investigation. Future precision oncology approaches may incorporate host and viral genetic markers to identify and stratify high-risk HPV-negative OSCC patients.
Downloads
References
- Huang X, Kang L, Bi J. Epidemiology of oral health in older adults aged 65 or over: prevalence, risk factors and prevention. Aging Clin Exp Res. 202523;37(1):193. doi: 10.1007/s40520-025-03110-8
» https://doi.org/10.1007/s40520-025-03110-8
2- Hübbers CU, Akgül B. HPV and cancer of the oral cavity. Virulence. 2015;6(3):244-8. doi: 10.1080/21505594.2014.999570
» https://doi.org/10.1080/21505594.2014.999570
3- Su ZY, Siak PY, Leong CO, Cheah SC. The role of Epstein-Barr virus in nasopharyngeal carcinoma. Front Microbiol. 2023;14:1116143. doi: 10.3389/fmicb.2023.1116143
» https://doi.org/10.3389/fmicb.2023.1116143
4- Blankson PK, Parkins GE, Blankson HN, Fasola AO, Pappoe-Ashong PJ, Boamah MO, et al. Herpesviruses and human papillomaviruses in saliva and biopsies of patients with orofacial tumors. Clinics (Sao Paulo). 2024;79:100477. doi: 10.1016/j.clinsp.2024.100477
» https://doi.org/10.1016/j.clinsp.2024.100477
5- Vijayvargiya P, Trivedi S, Rupji M, Song H, Liu Y, Jiang R, et al. Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) staging for selected and nonselected oropharyngeal squamous cell carcinomas. Oncologist. 2022;27(1):48-56. doi: 10.1093/oncolo/oyab001
» https://doi.org/10.1093/oncolo/oyab001
6- Burr AR, Harari PM, Ko HC, Chen S, Yu M, Baschnagel AM, et al. HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients. Otorhinolaryngol Head Neck Surg. 2018;3(1). doi: 10.15761/OHNS.1000160
» https://doi.org/10.15761/OHNS.1000160
7- Das R, Kumar R, Rai AK, Sarma A, Kakoti L, Chandra Kataki A, et al. HPV and p16 expression association with 5-year survival in oral squamous cell carcinoma patients of north-east India. Adv Cancer Biol - Metastasis. 2024;10:100115. doi: 10.1016/j.adcanc.2024.100115
» https://doi.org/10.1016/j.adcanc.2024.100115
8- Pérez-Islas E, García-Carrancá A, Acosta-Gio E, Reynoso-Noverón N, Maldonado-Martínez HA, Guido-Jiménez M, et al. Prognostic importance of DNA from human papillomavirus in patients with oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2022;27(2):e150-8. doi: 10.4317/medoral.25092
» https://doi.org/10.4317/medoral.25092
9- Dunmire SK, Verghese PS, Balfour HH. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84-92. doi: 10.1016/j.jcv.2018.03.001
» https://doi.org/10.1016/j.jcv.2018.03.001
10- Thomas R, Macsween KF, McAulay K, Clutterbuck D, Anderson R, Reid S, et al. Evidence of shared Epstein-Barr viral isolates between sexual partners, and low level EBV in genital secretions. J Med Virol. 2006;78(9):1204-9. doi: 10.1002/jmv.20682
» https://doi.org/10.1002/jmv.20682
11- Silva JM, Alves CE, Pontes GS. Epstein-Barr virus: the mastermind of immune chaos. Front Immunol. 2024;15:1297994. doi: 10.3389/fimmu.2024.1297994
» https://doi.org/10.3389/fimmu.2024.1297994
12- Guidry JT, Birdwell CE, Scott RS. Epstein-Barr virus in the pathogenesis of oral cancers. Oral Dis. 2018;24(4):497-508. doi: 10.1111/odi.12656
» https://doi.org/10.1111/odi.12656
13- Trivic A, Milovanovic J, Kablar D, Tomic A, Folic M, Jotic A, et al. Friend or Foe? Exploring the role of cytomegalovirus (HCMV) infection in head and neck tumors. Biomedicines. 2024;12(4):872. doi: 10.3390/biomedicines12040872
» https://doi.org/10.3390/biomedicines12040872
14- Watanabe A, Mizoguchi I, Hasegawa H, Katahira Y, Inoue S, Sakamoto E, et al. A Chaperone-Like role for EBI3 in collaboration with calnexin under inflammatory conditions. Front Immunol. 2021;12:757669. doi: 10.3389/fimmu.2021.757669
» https://doi.org/10.3389/fimmu.2021.757669
15- Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH, et al. IL-35 over-expression is associated with genesis of gastric cancer. Asian Pac J Cancer Prev. 2015;16(7):2845-9. doi: 10.7314/apjcp.2015.16.7.2845
» https://doi.org/10.7314/apjcp.2015.16.7.2845
16- Gu Q, Wu H, Cheng Z, Zhi X, Song Q, Chen X, et al. Low EBI3 expression promotes the malignant degree of gastric cancer. Dis Markers. 2022;2022:5588043. doi: 10.1155/2022/5588043
» https://doi.org/10.1155/2022/5588043
17- Jiang J, Liu X. Upregulated EBI3 correlates with poor outcome and tumor progression in breast cancer. Oncol Res Treat. 2018;41(3):111-5. doi: 10.1159/000484935
» https://doi.org/10.1159/000484935
18- Liang Y, Chen Q, Du W, Chen C, Li F, Yang J, et al. Epstein-Barr Virus-Induced Gene 3 (EBI3) blocking leads to induce antitumor cytotoxic t lymphocyte response and suppress tumor growth in colorectal cancer by bidirectional reciprocal-regulation STAT3 signaling pathway. Mediators Inflamm. 2016;2016:3214105. doi: 10.1155/2016/3214105
» https://doi.org/10.1155/2016/3214105
19- Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011;17(19):6272-86. doi: 10.1158/1078-0432.CCR-11-0060
» https://doi.org/10.1158/1078-0432.CCR-11-0060
20- Song Q, Chen X, Hu W, Mei G, Yang X, Wu H. Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection. Oncol Lett. 2018;15(5):7751-9. doi: 10.3892/ol.2018.8272
» https://doi.org/10.3892/ol.2018.8272
21- Zhang Y, Sun H, Wu H, Tan Q, Xiang K. Interleukin 35 is an independent prognostic factor and a therapeutic target for nasopharyngeal carcinoma. Contemp Oncol (Pozn). 2015;19(2):120-4. doi: 10.5114/wo.2014.44754
» https://doi.org/10.5114/wo.2014.44754
22- Wang J, Lu L, Huang K, Wei G, Tang J. Associations of Epstein-Barr virus-induced gene 3 polymorphisms and expression with osteosarcoma risk. Int J Clin Exp Pathol. 2016;9(10):10721-7.
23- Guan SY, Liu LN, Mao YM, Zhao CN, Wu Q, Dan YL, et al. Association between Interleukin 35 gene single nucleotide polymorphisms and systemic lupus erythematosus in a chinese han population. Biomolecules. 2019;9(4):157. doi: 10.3390/biom9040157
» https://doi.org/10.3390/biom9040157
24- Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ, et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res. 2010;70(22):9073-83. doi: 10.1158/0008-5472.CAN-10-1832
» https://doi.org/10.1158/0008-5472.CAN-10-1832
25- Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44(D1):D877-81. doi: 10.1093/nar/gkv1340
» https://doi.org/10.1093/nar/gkv1340
26- She Y, Nong X, Zhang M, Wang M. Epstein-Barr virus infection and oral squamous cell carcinoma risk: a meta-analysis. PLoS One. 2017;12(10):e0186860. doi: 10.1371/journal.pone.0186860
» https://doi.org/10.1371/journal.pone.0186860
27- Sivakumar S, Gupta AA, Nik Mohd Rosdy NM, Venkiteswaran A, Raj AT, Awan KH. Assessing the potential association between Epstein-Barr virus and oral squamous cell carcinoma: a systematic review and meta-analysis. Transl Cancer Res. 2020;9(4):3092-100. doi: 10.21037/tcr.2020.01.09
» https://doi.org/10.21037/tcr.2020.01.09
28- S D, Ramalingam K, Ramani P, Krishnan M. A concordance between clinical and pathological tumor staging of oral squamous cell carcinoma: an institutional study. Cureus. 2024;16(6):e61584. doi: 10.7759/cureus.61584
» https://doi.org/10.7759/cureus.61584
29- Kirtane K, St John M, Fuentes-Bayne H, Patel SP, Mardiros A, Xu H, et al. Genomic immune evasion: diagnostic and therapeutic opportunities in head and neck squamous cell carcinomas. J Clin Med. 2022;11(24):7259. doi: 10.3390/jcm11247259
» https://doi.org/10.3390/jcm11247259
30- Kikuchi K, Noguchi Y, Rivera MW, Hoshino M, Sakashita H, Yamada T, et al. Detection of Epstein-Barr virus genome and latent infection gene expression in normal epithelia, epithelial dysplasia, and squamous cell carcinoma of the oral cavity. Tumour Biol. 2016;37(3):3389-404. doi: 10.1007/s13277-015-4167-7
» https://doi.org/10.1007/s13277-015-4167-7
31- Rahman R, Poomsawat S, Juengsomjit R, Buajeeb W. Overexpression of Epstein-Barr virus-encoded latent membrane protein-1 (LMP-1) in oral squamous cell carcinoma. BMC Oral Health. 2019;19(1):142. doi: 10.1186/s12903-019-0832-3
32- Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012;22(2):144-53. doi: 10.1016/j.semcancer.2012.01.004
» https://doi.org/10.1016/j.semcancer.2012.01.004
33- Ma N, Fang Y, Xu R, Zhai B, Hou C, Wang X, et al. Ebi3 promotes T- and B-cell division and differentiation via STAT3. Mol Immunol. 2019;107:61-70. doi: 10.1016/j.molimm.2019.01.009
» https://doi.org/10.1016/j.molimm.2019.01.009
34- Posadas-Sánchez R, Del Carmen González-Salazar M, Cardoso-Saldaña G, Andrés Criales-Vera S, Reyes-Barrera J, Pérez-Hernández N, et al. Epstein-Barr virus-induced gene 3 (EBI3) single nucleotide polymorphisms and their association with central obesity and risk factors for cardiovascular disease: The GEA study. Cytokine. 2020;135:155225. doi: 10.1016/j.cyto.2020.155225
» https://doi.org/10.1016/j.cyto.2020.155225
35- Zheng R, Liu H, Song P, Feng Y, Qin L, Huang X, et al. Epstein-Barr virus-induced gene 3 (EBI3) polymorphisms and expression are associated with susceptibility to pulmonary tuberculosis. Tuberculosis (Edinb). 2015;95(4):497-504. doi: 10.1016/j.tube.2015.03.009
» https://doi.org/10.1016/j.tube.2015.03.009
36- Chehboun S, Labrecque-Carbonneau J, Pasquin S, Meliani Y, Meddah B, Ferlin W, et al. Epstein-Barr virus-induced gene 3 (EBI3) can mediate IL-6 trans-signaling. J Biol Chem. 2017;292(16):6644-56. doi: 10.1074/jbc.M116.762021
» https://doi.org/10.1074/jbc.M116.762021
37- Scott EN, Ye C, Yano H, Lipatova Z, Brunazzi E, Vignali KM, et al. Ebi3 Binding to IFN-? and IL-10 limits their function. J Immunol. 2024;213(8):1115-24. doi: 10.4049/jimmunol.2400236
» https://doi.org/10.4049/jimmunol.2400236
38- Hildenbrand K, Bohnacker S, Menon PR, Kerle A, Prodjinotho UF, Hartung F, et al. Human interleukin-12a and EBI3 are cytokines with anti-inflammatory functions. Sci Adv. 2023;9(43):eadg6874. doi: 10.1126/sciadv.adg6874
» https://doi.org/10.1126/sciadv.adg6874
39- Wirtz S, Becker C, Fantini MC, Nieuwenhuis EE, Tubbe I, Galle PR, et al. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation. J Immunol. 2005;174(5):2814-24. doi: 10.4049/jimmunol.174.5.2814
» https://doi.org/10.4049/jimmunol.174.5.2814
40- Yonekura S. Epstein-Barr Virus-induced Gene 3 as a novel biomarker in metastatic melanoma with infiltrating CD8+ T cells: a study based on The Cancer Genome Atlas (TCGA). Anticancer Res. 2022;42(1):511-7. doi: 10.4049/jimmunol.174.5.2814
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Marko Simonovic, Ruzica Kozomara, Sasa Jovic, Gordana Velikic, Elizabeta Ristanovic, Nikoleta Djordjevski, Danijela Djuric-Petkovic, Srboljub Stosic, Gordana Supic
This work is licensed under a Creative Commons Attribution 4.0 International License.
Todo o conteúdo do periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons do tipo atribuição CC-BY.
